2.56
price down icon12.93%   -0.38
after-market Dopo l'orario di chiusura: 2.50 -0.06 -2.34%
loading

Gridai Technologies Corp Borsa (GRDX) Ultime notizie

pulisher
Dec 09, 2025

Entero Regains Nasdaq Compliance With Grid AI Acquisition - Monroe Evening News

Dec 09, 2025
pulisher
Dec 09, 2025

GridAI Technologies Corp. Announces Appointment of Marshall Chapin as Chief Executive Officer of wholly-owned operating subsidiary GridAI, Inc - Black Hills Pioneer

Dec 09, 2025
pulisher
Dec 07, 2025

Entero Therapeutics, Inc. Announces Corporate Name Change to GridAI Technologies Corp. and New Ticker Symbol "GRDX" - Lohud

Dec 07, 2025
pulisher
Dec 05, 2025

GridAI Technologies Announces Board Changes and Rebranding - The Globe and Mail

Dec 05, 2025
pulisher
Dec 05, 2025

GridAI appoints Marshall Chapin as CEO of energy-orchestration subsidiary - Yahoo Finance

Dec 05, 2025
pulisher
Dec 04, 2025

GridAI Technologies Corp. Announces Board and Committee Changes - marketscreener.com

Dec 04, 2025
pulisher
Dec 04, 2025

GridAI Technologies Corp. Appoints Marshall Chapin as Chief Executive Officer of wholly-owned operating subsidiary GridAI, Inc - marketscreener.com

Dec 04, 2025
pulisher
Dec 04, 2025

GridAI Technologies (NASDAQ: GRDX) taps Marshall Chapin to lead AI data-center grid unit - Stock Titan

Dec 04, 2025
pulisher
Nov 28, 2025

Entero Therapeutics Stock Gains 5% Ahead Of Name Change To GridAI - Nasdaq

Nov 28, 2025
pulisher
Nov 28, 2025

Entero Therapeutics Stock Jumps After Company Rebrands As GridAI Technologies Corp. - MSN

Nov 28, 2025
pulisher
Nov 28, 2025

Entero Therapeutics (ENTO) to Rebrand as GridAI (GRDX) Technologies - GuruFocus

Nov 28, 2025
pulisher
Nov 28, 2025

Entero Therapeutics to Change Name to GridAI Technologies - marketscreener.com

Nov 28, 2025
pulisher
Nov 28, 2025

Entero Therapeutics stock rises ahead of name change to GridAI By Investing.com - Investing.com South Africa

Nov 28, 2025
pulisher
Nov 28, 2025

Entero Therapeutics stock rises ahead of name change to GridAI - Investing.com India

Nov 28, 2025
pulisher
Nov 19, 2025

Entero's Grid AI Prepares for Major U.S. Expansion with New Leadership Appointments to Accelerate AI Infrastructure Strategy - Greenville Online

Nov 19, 2025
pulisher
Nov 19, 2025

Entero (NASDAQ: ENTO) Grid AI LOI with First Hyperscaler AI Data-Center Client - Stock Titan

Nov 19, 2025
pulisher
Nov 16, 2025

Entero Subsidiary Grid AI Accelerates Expansion into Hyperscaler AI Data Center Market with Integration of LV Grid - St. Cloud Times

Nov 16, 2025
pulisher
Nov 14, 2025

Entero Therapeutics, Inc., Launches Grid AI Corp to Redefine How AI Infrastructure Connects to the Power Grid - Record Searchlight

Nov 14, 2025
pulisher
Nov 13, 2025

Entero Therapeutics (NASDAQ: ENTO) to name U.S. CEO and Executive Chairman for Grid AI - Stock Titan

Nov 13, 2025
pulisher
Oct 30, 2025

Entero Therapeutics (NASDAQ: ENTO) acquires 100% of Grid AI, regains Nasdaq compliance - Stock Titan

Oct 30, 2025
pulisher
Oct 14, 2025

$2.5B market opportunity: Entero Therapeutics acquires GRID AI to scale grid orchestration - Stock Titan

Oct 14, 2025
pulisher
Oct 01, 2025

ENTERO THERAPEUTICS (ENTO) Acquires 100% of GRID AI, a Grid-Edge AI Platform Optimizing Next-Gen Power Demand - Yahoo Finance

Oct 01, 2025
pulisher
Aug 14, 2025

Entero Therapeutics Plans 1:3 Reverse Split as Shares Drop Below Nasdaq Minimum - Stock Titan

Aug 14, 2025
pulisher
Aug 11, 2025

Entero Therapeutics, Inc. Announces $3.0 Million Private Placement Priced at the Market Under Nasdaq Rules - Stock Titan

Aug 11, 2025
pulisher
Mar 07, 2025

Entero Therapeutics, Inc. Chief Financial Officer Changes - marketscreener.com

Mar 07, 2025
pulisher
Feb 14, 2025

Entero Therapeutics Appoints Richard Paolone as CEO - marketscreener.com

Feb 14, 2025
pulisher
Feb 07, 2025

Entero Therapeutics Secures $2 Million Revolving Loan; Appoints Three New Board Members - marketscreener.com

Feb 07, 2025
pulisher
Jan 26, 2025

Entero Therapeutics, Inc. announced that it has received $2 million in funding from 1396974 B.C. Ltd - marketscreener.com

Jan 26, 2025
pulisher
Nov 27, 2024

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates STAF, ATSG, ENTO, AVTE on Behalf of Shareholders - marketscreener.com

Nov 27, 2024
pulisher
Nov 14, 2024

Entero Therapeutics CEO James Sapirstein to Moderate the 2024 BioFlorida Annual Innovation Conference CEO Forum - marketscreener.com

Nov 14, 2024
pulisher
Nov 13, 2024

Entero Therapeutics Announces 99% Reverse Merger Deal with Journey's Cancer Platform - Stock Titan

Nov 13, 2024
pulisher
Nov 12, 2024

Journey Therapeutics, Inc. entered into a binding term sheet to acquire Entero Therapeutics, Inc. in a reverse merger transaction. - marketscreener.com

Nov 12, 2024
pulisher
Sep 10, 2024

Entero Therapeutics Signs Letter of Intent to License and Commercialize Remote Patient and Machine Vision Clinical Trial Management Platform from Data Vault Holdings - marketscreener.com

Sep 10, 2024
pulisher
Aug 23, 2024

Entero Therapeutics, Inc. Receives Nasdaq Notification Regarding Delayed Form 10-Q - marketscreener.com

Aug 23, 2024
pulisher
Aug 01, 2024

Entero Therapeutics Chairman and CEO James Sapirstein Provides Business Update with Focus on Latiglutenase Development Program - marketscreener.com

Aug 01, 2024
pulisher
Jul 31, 2024

Entero Therapeutics’ Chairman and CEO James Sapirstein Provides Business Update with Focus on Latiglutenase Development Program - marketscreener.com

Jul 31, 2024
pulisher
May 20, 2024

ENTOEntero Therapeutics Latest Stock News & Market Updates - Stock Titan

May 20, 2024
pulisher
Apr 17, 2024

First Wave BioPharma CEO James Sapirstein to Present at the Planet MicroCap Showcase - marketscreener.com

Apr 17, 2024
pulisher
Apr 15, 2024

First Wave BioPharma CEO James Sapirstein to Participate in 2024 Longwood Healthcare Leaders Conference - marketscreener.com

Apr 15, 2024
pulisher
Jan 17, 2024

First Wave BioPharma CEO to Present at the Sequire Investor Summit 2024 in Puerto Rico - marketscreener.com

Jan 17, 2024
$38.53
price up icon 0.36%
$98.64
price up icon 3.39%
$31.57
price up icon 0.83%
$93.81
price down icon 1.05%
biotechnology ONC
$310.67
price down icon 2.63%
$196.92
price down icon 0.05%
Capitalizzazione:     |  Volume (24 ore):